Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582114 · ClinicalTrials.gov registry record · Phase 3
Hypertension in Hemodialysis Patients (Aim 3)
A Phase 3 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00582114 is a Phase 3 study that was terminated before completion, run by Indiana University. The registered enrollment target is 200 participants.
The verdict
NCT00582114, a Phase 3 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
We will directly test the hypothesis that an initial strategy of lisinopril-based therapy will be more effective than atenolol-based therapy in causing regression of left ventricular hypertrophy (LVH) over one year in patients with hemodialysis hypertension despite similar degree of BP reduction.
Interventions
- DRUG Atenolol
- DRUG Lisinopril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2005-08 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00582114
The ClinicalTrials.gov registry entry for NCT00582114 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atenolol is the first listed.
NCT00582114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00582114 about?
NCT00582114 is a clinical study titled "Hypertension in Hemodialysis Patients (Aim 3)". We will directly test the hypothesis that an initial strategy of lisinopril-based therapy will be more effective than atenolol-based therapy in causing regression of left ventricular hypertrophy (LVH) over one year in patients with hemodialysis hypertension despite similar degree of BP reduction.
What is the current status of trial NCT00582114?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2005-08. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00582114?
The interventions under investigation include: Atenolol (DRUG), Lisinopril (DRUG).
Who is sponsoring clinical trial NCT00582114?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.